ECSP11011415A - Piperidinas sustituidas como antagonistas de ccr3. - Google Patents
Piperidinas sustituidas como antagonistas de ccr3.Info
- Publication number
- ECSP11011415A ECSP11011415A EC2011011415A ECSP11011415A ECSP11011415A EC SP11011415 A ECSP11011415 A EC SP11011415A EC 2011011415 A EC2011011415 A EC 2011011415A EC SP11011415 A ECSP11011415 A EC SP11011415A EC SP11011415 A ECSP11011415 A EC SP11011415A
- Authority
- EC
- Ecuador
- Prior art keywords
- ccr3
- antigonist
- piperidins
- replaced
- present
- Prior art date
Links
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 title abstract 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
- C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Objeto de la presente invención son compuestos novedosos sustituidos de la fórmula 1,en la que A, R1, R2, R3 y R4 se definen como en la descripción. Otro objeto de la presente invención es proporcionar antagonistas de CCR3, más particularmente proporcionar composiciones farmacéuticas que comprenden un vehículo farmacéuticamente aceptable y una cantidad terapéuticamente eficaz de al menos uno de los compuestos de la presente invención o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16270509P | 2009-03-24 | 2009-03-24 | |
| US31671310P | 2010-03-23 | 2010-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP11011415A true ECSP11011415A (es) | 2011-11-30 |
Family
ID=42136100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2011011415A ECSP11011415A (es) | 2009-03-24 | 2011-08-24 | Piperidinas sustituidas como antagonistas de ccr3. |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP2411372B1 (es) |
| JP (1) | JP5744003B2 (es) |
| KR (1) | KR101665955B1 (es) |
| CN (1) | CN102361858B (es) |
| AU (1) | AU2010229975B2 (es) |
| BR (1) | BRPI1009854A2 (es) |
| CA (1) | CA2753825C (es) |
| CL (1) | CL2011002278A1 (es) |
| CO (1) | CO6450678A2 (es) |
| CR (1) | CR20110524A (es) |
| DO (1) | DOP2011000297A (es) |
| EC (1) | ECSP11011415A (es) |
| ES (1) | ES2488821T3 (es) |
| GT (1) | GT201100241A (es) |
| HK (1) | HK1166798A1 (es) |
| IL (1) | IL214858A (es) |
| MX (1) | MX2011010049A (es) |
| MY (1) | MY169288A (es) |
| NZ (1) | NZ594923A (es) |
| PE (1) | PE20120519A1 (es) |
| RU (1) | RU2524573C2 (es) |
| SG (1) | SG174211A1 (es) |
| WO (1) | WO2010111348A1 (es) |
| ZA (1) | ZA201106511B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX338725B (es) | 2010-07-16 | 2016-04-28 | Abbvie Bahamas Ltd | Ligando de fosfina para reacciones cataliticas. |
| US9255074B2 (en) | 2010-07-16 | 2016-02-09 | Abbvie Inc. | Process for preparing antiviral compounds |
| AU2011278927B2 (en) | 2010-07-16 | 2015-05-21 | Abbvie Ireland Unlimited Company | Process for preparing antiviral compounds |
| US8975443B2 (en) | 2010-07-16 | 2015-03-10 | Abbvie Inc. | Phosphine ligands for catalytic reactions |
| TWI558400B (zh) * | 2011-03-18 | 2016-11-21 | 艾伯維有限公司 | 苯基尿嘧啶化合物之調配物 |
| US20160375017A1 (en) | 2015-06-26 | 2016-12-29 | Abbvie Inc. | Solid Pharmaceutical Compositions for Treating HCV |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1219626B1 (en) * | 1999-09-20 | 2005-06-01 | Fuji Photo Film Co., Ltd. | Compounds for fluorescence labeling |
| EP1218401B1 (de) * | 1999-09-22 | 2004-06-16 | Aventis Pharma Deutschland GmbH | 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung |
| DE10051981A1 (de) * | 2000-10-20 | 2002-05-02 | Bayer Ag | Substituierte Phenyluracile |
| WO2007138242A1 (en) * | 2006-05-30 | 2007-12-06 | Arrow Therapeutics Limited | Biphenyl derivatives and their use in treating hepatitis c |
| KR101552474B1 (ko) * | 2007-09-17 | 2015-09-11 | 애브비 바하마스 리미티드 | Ｃ형 간염 치료용 우라실 또는 티민 유도체 |
| CN105693626A (zh) * | 2007-09-17 | 2016-06-22 | 艾伯维巴哈马有限公司 | 治疗丙型肝炎的尿嘧啶或胸腺嘧啶衍生物 |
| BRPI0916233A2 (pt) * | 2008-07-23 | 2018-03-13 | F.Hoffman-La Roche Ag | compostos heterocíclicos antivirais |
-
2010
- 2010-03-24 WO PCT/US2010/028433 patent/WO2010111348A1/en active Application Filing
- 2010-03-24 EP EP10711968.7A patent/EP2411372B1/en active Active
- 2010-03-24 AU AU2010229975A patent/AU2010229975B2/en active Active
- 2010-03-24 MX MX2011010049A patent/MX2011010049A/es active IP Right Grant
- 2010-03-24 NZ NZ594923A patent/NZ594923A/xx unknown
- 2010-03-24 RU RU2011142757/04A patent/RU2524573C2/ru active
- 2010-03-24 BR BRPI1009854-2A patent/BRPI1009854A2/pt not_active Application Discontinuation
- 2010-03-24 CA CA2753825A patent/CA2753825C/en active Active
- 2010-03-24 CN CN201080013374.7A patent/CN102361858B/zh active Active
- 2010-03-24 ES ES10711968.7T patent/ES2488821T3/es active Active
- 2010-03-24 KR KR1020117024825A patent/KR101665955B1/ko active IP Right Grant
- 2010-03-24 MY MYPI2011004471A patent/MY169288A/en unknown
- 2010-03-24 PE PE2011001686A patent/PE20120519A1/es active IP Right Grant
- 2010-03-24 SG SG2011063179A patent/SG174211A1/en unknown
- 2010-03-24 JP JP2012502196A patent/JP5744003B2/ja active Active
-
2011
- 2011-08-24 EC EC2011011415A patent/ECSP11011415A/es unknown
- 2011-08-28 IL IL214858A patent/IL214858A/en active IP Right Grant
- 2011-09-06 ZA ZA2011/06511A patent/ZA201106511B/en unknown
- 2011-09-14 CL CL2011002278A patent/CL2011002278A1/es unknown
- 2011-09-20 GT GT201100241A patent/GT201100241A/es unknown
- 2011-09-21 CO CO11123197A patent/CO6450678A2/es active IP Right Grant
- 2011-09-23 DO DO2011000297A patent/DOP2011000297A/es unknown
- 2011-10-04 CR CR20110524A patent/CR20110524A/es unknown
-
2012
- 2012-08-01 HK HK12107568.3A patent/HK1166798A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102361858B (zh) | 2014-07-23 |
| CO6450678A2 (es) | 2012-05-31 |
| NZ594923A (en) | 2013-11-29 |
| PE20120519A1 (es) | 2012-06-03 |
| JP5744003B2 (ja) | 2015-07-01 |
| EP2411372A1 (en) | 2012-02-01 |
| CA2753825A1 (en) | 2010-09-30 |
| RU2011142757A (ru) | 2013-04-27 |
| CA2753825C (en) | 2017-10-17 |
| WO2010111348A1 (en) | 2010-09-30 |
| AU2010229975A1 (en) | 2011-09-29 |
| MX2011010049A (es) | 2011-10-11 |
| IL214858A (en) | 2015-05-31 |
| SG174211A1 (en) | 2011-10-28 |
| MY169288A (en) | 2019-03-21 |
| JP2012521990A (ja) | 2012-09-20 |
| GT201100241A (es) | 2015-08-19 |
| KR20110137372A (ko) | 2011-12-22 |
| HK1166798A1 (en) | 2012-11-09 |
| AU2010229975B2 (en) | 2015-05-21 |
| IL214858A0 (en) | 2011-11-30 |
| CR20110524A (es) | 2012-01-19 |
| CN102361858A (zh) | 2012-02-22 |
| BRPI1009854A2 (pt) | 2015-08-25 |
| ES2488821T3 (es) | 2014-08-29 |
| RU2524573C2 (ru) | 2014-07-27 |
| KR101665955B1 (ko) | 2016-10-13 |
| ZA201106511B (en) | 2012-05-30 |
| DOP2011000297A (es) | 2011-10-15 |
| EP2411372B1 (en) | 2014-07-23 |
| CL2011002278A1 (es) | 2012-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP11011427A (es) | Piperidinas sustituidas como antagonistas de ccr3. | |
| UY32543A (es) | Análogos de isoxazol-3(2h)-ona como agentes terapéuticos | |
| ECSP12012292A (es) | Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos | |
| CR11683A (es) | Piridinas y pirazinas como inhibidores de p13k | |
| NI201200089A (es) | INHIBIDORES DE N1 - PIRAZOLOESPIROCETONA ACETIL - CoA CARBOXILASA. | |
| ECSP11010880A (es) | Compuestos orgánicos | |
| ECSP12012293A (es) | Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos | |
| SV2011003855A (es) | Heteroarilos sustituidos | |
| CR9214A (es) | 2-fenilindoles como antagonistas del receptor de la prostaglandina d2 | |
| DOP2009000278A (es) | Derivados de bencimidazol | |
| ECSP11011415A (es) | Piperidinas sustituidas como antagonistas de ccr3. | |
| SV2010003459A (es) | Derivados de pirimidina 934 | |
| CR20110381A (es) | Antagonistas de 4-azetidinil-1-heteroaril-ciclohexanol de ccr2 | |
| PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
| BRPI0924617A8 (pt) | Compostos heterociclicos de fenoximetila | |
| CR20110093A (es) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos | |
| PE20142450A1 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| GT200900309A (es) | Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica | |
| CO6331308A2 (es) | Derivados de carboxamidaindazol con actividad sobre el receptor cb1 y composiciones farmaceuticas que los comprenden | |
| PE20170427A1 (es) | Peptidos como agonistas de la oxitocina | |
| CR20110535A (es) | Antagonistas ccr3 de arylsulfonamida 2,5-disustituidas | |
| CO6361921A2 (es) | 3-aminociclopentancarboxamidas | |
| DOP2012000078A (es) | Derivados de espirolactama y usos de los mismos | |
| PE20141168A1 (es) | Derivados de pirazolidin-3-ona | |
| ATE546448T1 (de) | Urotensin-ii-rezeptorantagonisten |